Exploring potential exciting partnerships at the J.P. Morgan Healthcare Conference
“Grünenthal is constantly exploring new R&D partnerships and attractive growth opportunities.”
The annual J.P. Morgan Healthcare Conference brings together stakeholders from around the world to share information and explore opportunities to advance the development of medicines together. The event took place for the 38th time, attracting more than 9,000 attendees from almost 500 private and public companies, including industry leaders as well as emerging fast-growth companies, innovative technology creators and members of the investment community. If you’re in the healthcare industry, it’s the place to be.
The high-calibre Grünenthal team participated in this year’s conference in San Francisco, where they shared insights into the company’s product portfolio, innovation pipeline and current partnerships. Grünenthal has pursued a consistent growth path in recent years and expanded its portfolio by a series of acquisitions with a total value of more than $ 1.3 billion since 2016. Eager to continue this journey by either acquiring established brands for the treatment of pain or entering into research partnerships to co-develop innovative medicines, the team discussed potential collaborations with partners who share the company’s passion for creating innovative pain medicines to improve quality of life for patients.